Yang, Lan, and Aixia Ma. “Cost-Utilities Analysis of Polatuzumab Vedotin Combined With Bendamustine and Rituximab for Relapsed Refractory Diffuse Large B-Cell Lymphoma Which Is Unsuited for Hematopoietic Stem Cell Transplantation”. Frontiers in Business, Economics and Management 8, no. 3 (April 25, 2023): 178–184. Accessed May 20, 2026. https://drpress.org/ojs/index.php/fbem/article/view/7835.